CTOs on the Move

New York Proton Center

www.nyproton.com

 
New York Proton Center is creating the gold standard for proton therapy, giving new hope to patients living with cancer. In partnership with leading academic medical centers—Memorial Sloan Kettering Cancer Center, Montefiore Health System, Mount Sinai Health System, and ProHEALTH as manager—New York Proton Center brings together expert oncologists, clinical care teams, and researchers to improve cancer care and advance the clinical evidence for proton therapy.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Martin Howard
Chief Information Officer Profile

Similar Companies

United Methodist Communities

You will find comfort, security, and gracious services that exceed your expectations in our communities. A caring staff will provide thoughtful attention to your needs. Old friends will want to visit. New neighbors will welcome you. The amenities of shops, restaurants, entertainment, events and churches are readily accessible in town. Year after year, residents and staff award our communities the highest satisfaction ratings in an independent survey.

Blue Cross Blue Shield of Kansas City (BCBSKC)

Blue Cross Blue Shield of Kansas City (BCBSKC) is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Blue Cross Blue Shield of Kansas City (BCBSKC) is based in Kansas City, MO. You can find more information on Blue Cross Blue Shield of Kansas City (BCBSKC) at www.bcbskc.com

Upswing Health

Upswing helps you #getbackintheswing of things. We help athletes identify injuries and find the best path to recovery.

Hemostasis Corp

Hemostasis Corp is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OncoCell MDx

OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of our pipeline. The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease. Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.